NOVAVAX INC Total Liabilities
NOVAVAX INC (NVAX) had Total Liabilities of $1.15 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-06
- 2026-06-30: Liabilities $1.15B.
- 2026-03-31: Liabilities $1.19B.
- 2025-12-31: Liabilities $1.30B.
- 2025-09-30: Liabilities $1.34B.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $1.15B 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.19B 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $1.30B 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $1.34B 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.30B 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $1.37B 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $2.18B 10-K · filed 2026-02-26 | |
| 2024-09-30 | $2.24B 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $2.25B 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $2.22B 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $2.51B 10-K · filed 2025-02-27 | |
| 2023-09-30 | $2.34B 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $2.44B 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $2.44B 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $2.89B 10-K · filed 2024-02-28 | |
| 2022-09-30 | $2.83B 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $3.04B 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $2.77B 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $2.93B 10-K · filed 2023-02-28 | |
| 2021-09-30 | $2.10B 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $2.00B 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $1.57B 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $955.27M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $637.76M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $547.88M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $352.04M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $358.97M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $354.65M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $374.88M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $371.90M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $375.91M 10-K · filed 2020-03-11 | |
| 2018-09-30 | $377.16M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $373.51M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $375.44M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $404.23M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $408.23M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $414.77M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $390.60M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $399.85M 10-K · filed 2018-03-14 | |
| 2016-09-30 | $409.84M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $414.89M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $407.07M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $93.37M 10-K · filed 2017-02-27 | |
| 2015-09-30 | $37.62M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $37.09M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $39.13M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $46.38M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $30.86M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $30.26M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $27.54M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $31.89M 10-K · filed 2015-02-27 | $32.70M 10-K · filed 2014-03-12 |
| 2013-09-30 | $28.50M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $23.69M 10-Q · filed 2013-08-08 | |
| 2013-03-31 | $21.14M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $22.11M 10-K · filed 2014-03-12 | |
| 2012-09-30 | $19.17M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $15.90M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $14.31M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $12.73M 10-K · filed 2013-03-12 | |
| 2011-09-30 | $12.49M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $13.07M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $15.79M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |